Targeting renal cell carcinoma with a HIF-2 antagonist Wenfang Chen , Haley Hill , Alana Christie , Min Soo Kim , Eboni Holloman , Andrea Pavia-Jimenez , Farrah Homayoun , Yuanqing Ma , Nirav Patel , Paul Yell , Guiyang Hao , Qurratulain Yousuf , Allison Joyce , Ivan Pedrosa , Heather Geiger , He Zhang , Jenny Chang , Kevin H. Gardner , Richard K. Bruick , Catherine Reeves , Tae Hyun Hwang , Kevin Courtney , Eugene Frenkel , Xiankai Sun , Naseem Zojwalla , Tai Wong , James P. Rizzi , Eli M. Wallace , John A. Josey , Yang Xie , Xian-Jin Xie , Payal Kapur , Renée M. McKay , James Brugarolas NATURE（2016）
摘要
The HIF-2 antagonist PT2399 is tested in mice bearing tumourgrafts derived from human renal cell cancers to demonstrate its efficacy, identify markers of sensitivity and characterize its effects.
更多 查看译文
关键词
Preclinical research, Cancer
AI 理解论文
溯源树
样例
